Mohs micrographic surgery for keratinocyte carcinomas: clinicopathological predictors of the number of stages

Abstract

Background

The number of Mohs stages needed to remove a keratinocyte carcinoma affects resource use, expenses, and repair complexity. This study aimed to identify clinicopathological predictors associated with increased or decreased stages and areas for further research.

Methods

A retrospective review was conducted from a single private practice with two Mohs surgeons of 2788 consecutive Mohs cases between January 2017 and December 2021, analyzing the average number of stages taken versus national norms (P = 0.21) and subgroups using unpaired t tests (*<0.05).

Results

Several tumor features were significantly associated with fewer stages: squamous cell carcinomas, Mohs appropriate use criteria score of 7 or 8, preoperative size <0.25 cm², tumors on the lips and extremities (including hands/fingers), and smoking. Clinicopathological features significantly associated with more stages included Mohs appropriate use criteria score of 9, recurrent skin cancers, basal cell carcinomas, tumor size of 2.25–3.99 cm², cancers on ears, solid organ transplant patients, treatment delays >180 days, and patients ≥90 years old.

Conclusions

Significant predictors exist for both increased and decreased numbers of Mohs micrographic surgery stages required to eradicate a tumor, which may help Mohs surgeons facilitate, plan, and allocate resources more effectively. Areas for further research in Mohs micrographic surgery are identified.

Keywords:

• Basal cell carcinoma
• clinicopathological predictors
• keratinocyte carcinoma
• Mohs micrographic surgery
• Mohs stages
• nonmelanoma skin cancer
• squamous cell carcinoma

Disclosure statement/Funding

No funding or potential conflict of interest was reported by the authors.